Introduction

Generalised pustular psoriasis (GPP) is an uncommon, persistent, and severe form of psoriasis that is distinct from the more prevalent plaque psoriasis. It is distinguished by extensive, erythematous skin eruptions coated with sterile pustules and accompanied by systemic symptoms such as fever, malaise, and leukocytosis. GPP is a dermatologic emergency because of its rapid progression and the danger of systemic consequences, such as multi-organ failure. While GPP can occur at any age, it usually appears in adulthood and can be fatal if not recognised and treated right away.¹

The severity and unpredictability of GPP flares set it apart from other dermatologic disorders. Patients may endure recurrent episodes or chronic disease, which can have a significant influence on their overall quality of life. Over the last decade, major improvements in understanding the immunopathogenesis of GPP have resulted in novel, targeted therapy approaches, but many hurdles remain.²

Overview and classification

GPP is classified as pustular psoriasis, a diverse group that includes more localised types such as palmoplantar pustulosis. Among these, GPP is the most severe and is frequently linked with systemic involvement.³ There are several classifications depending on clinical characteristics and illness progression.

Von Zumbusch Type: The most acute and severe variety, distinguished by the abrupt appearance of extensive pustules and systemic symptoms.

Annular Pustular Psoriasis is a subacute type with ring-shaped lesions and minimal systemic involvement.

Impetigo Herpetiformis: A rare pregnancy-related variation that poses a risk to both the mother and the foetus.³

Each subtype has a unique presentation, triggers, and therapeutic response, necessitating individualised diagnostic and treatment procedures.

Causes and risk factors

Genetic factors

Genetic predisposition plays an important role in GPP. Recent research has shown abnormalities in numerous genes that affect normal skin immunity:

IL36RN: Mutations in this gene, which encodes the interleukin-36 receptor antagonist, are detected in a substantial proportion of patients and result in uncontrolled IL-36 signalling, which promotes inflammation.⁴

CARD14: This gene, which is associated with both pustular and plaque psoriasis, regulates NF-kB activation.⁵

Mutations in AP1S3 may cause faulty autophagy and inflammation in keratinocytes.⁵

These genetic alterations are more common in early-onset and familial instances and can help guide diagnosis and treatment.

Immune disregulation

GPP is largely an autoinflammatory disorder caused by innate immune mechanisms. Cytokines such as IL-1, IL-36, TNF-\u03b1, IL-17, and IL-23 are heavily implicated in the illness process. IL-36, in particular, has emerged as a crucial participant, giving it a potential target for therapy.^{4 6}

Environmental and iatrogenic triggers

Several external variables can cause GPP flares, including:

• Infections (such as streptococcal pharyngitis and viral diseases)
• Medications (for example, corticosteroids, lithium, antimalarials, and NSAIDs)
• Pregnancy
• Stress and Psychological Trauma
• Sudden discontinuation of systemic corticosteroids⁷
• Understanding and avoiding these triggers is critical in treating chronic GPP

Clinical presentation

GPP often manifests as a sudden onset of painful, red skin covered in small, sterile pustules. These pustules can form into "lakes of pus," resulting in widespread desquamation and skin loss.¹

Cutaneous signs

• Erythema and Scaling
• Clusters of superficial, non-infective pustules
• Symmetrical involvement of the trunk and extremities
• In severe circumstances, erythroderma spreads rapidly across the entire body¹

Systemic symptoms

• High-grade fever with chills
• Fatigue and malaise
• Nausea and vomiting
• Joint pain (psoriatic arthritis)
• Weight loss¹

Laboratory findings

• Increased white blood cell count (leukocytosis)
• Elevated CRP and ESR
• Low calcium and low albumin levels
• Negative bacterial cultures from pustules (sterility)¹

Histopathology

• Skin biopsies typically reveal
• Subcorneal or intraepidermal pustules
• Neutrophilic infiltration in the epidermis
• Spongiform pustules in Kogoj
• Psoriasiform Epidermal Hyperplasia¹

Diagnosis

GPP is primarily diagnosed clinically; however, it can also be confirmed by laboratory and histology findings. A complete history, including medication use and potential triggers, is required. Genetic testing for IL36RN mutations may help in diagnosis, especially in early-onset or family cases.⁴

Differential diagnosis includes

• Acute generalised exanthematous pustulosis (AGEP)
• Stevens–Johnson syndrome
• Toxic Epidermal Necrolysis
• Subcutaneous pustular dermatosis

Treatment

GPP management necessitates immediate and vigorous action due to the possibility of systemic failure. The treatment aims are to control the acute flare, prevent complications, and sustain long-term remission.⁶

Hospitalisation

Severe flares frequently require hospitalisation for:

• Fluid and electrolyte management
• Monitoring vital signs and organ function
• Preventing and treating secondary infections⁶

Systemic therapies

Biologics

• Biologic drugs have transformed the treatment of GPP
• Spesolimab is a monoclonal antibody that targets the IL-36 receptor and is specifically approved to treat GPP flares⁶
• Secukinumab and ixekizumab are IL-17 inhibitors that are effective in pustular psoriasis⁸
• Guselkumab, which targets IL-23, has shown promise in pustular forms⁸
• Adalimumab and Infliximab are TNF-\u03b1 inhibitors used in severe, refractory patients⁹

Non-biological systemic agents

Methotrexate is effective for long-term disease control

Cyclosporine has a rapid onset of action and is frequently utilised in acute flares. Acitretin is a systemic retinoid that is particularly effective in treating pustular psoriasis⁶

Supportive care

• Topical steroids and emollients
• Pain and fever control
• Antibiotics (if a secondary infection is detected)
• Nutritional and psychological support⁶

Prognosis and complications

Prognosis

With the right treatment, most people recover from acute flares. However, the chance of recurrence is significant. Long-term prognosis depends on:

• Promptness and adequate care
• Control over underlying triggers
• Comorbidities
• Genetic predisposition⁶

Complications

1. Sepsis and Secondary Infections
2. Acute kidney or liver failure
3. Cardiovascular stress from fluid loss and inflammation
4. Psychological distress and decreased quality of life³

Pregnant patients require special care, as maternal and foetal outcomes can be negatively affected.

Summary

Generalised pustular psoriasis is a severe, inflammatory skin disorder with potentially fatal systemic complications. For effective management, fast recognition and a multidisciplinary approach are required. Recent advancements in targeted biologic treatments, including IL-36 inhibition, provide hope for better disease management and patient outcomes.⁶ However, further study is needed to improve treatment strategies and better understand the genetic basis of this complicated condition.⁴

FAQs

How does GPP differ from other types of psoriasis?

GPP is distinguished by extensive pustules, systemic symptoms, and a more abrupt and severe course than plaque psoriasis.¹

Are the pustules in GPP infective?

No, the pustules are sterile and caused by inflammation, not infection.¹

What causes a GPP flare?

Common triggers include infections, drug changes, stress, and corticosteroid withdrawal.⁷

Can GPP be fatal?

Yes, untreated or severe GPP can result in life-threatening complications like sepsis and organ failure.⁶

Is GPP hereditary?

There is a genetic component, particularly in cases involving IL36RN mutations, but not all cases are inherited.⁴

What is the role of biologics in GPP therapy?

Biologics target specific inflammatory pathways, allowing for rapid and effective management of GPP flares.⁶

How is GPP diagnosed?

The diagnosis is clinical, based on lab tests, skin biopsy, and, in certain cases, genetic testing.⁴

Can kids develop GPP?

Yes, although rare, paediatric cases do happen and are frequently connected with genetic alterations.⁴

How frequently do flares occur?

Flares vary in frequency; some people have a chronic condition, while others have episodic flares.⁶

Will lifestyle modifications help?

Yes, avoiding triggers, managing stress, and sticking to treatment regimens can help lessen flare frequency and intensity.⁷